secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2022-02-25T23:59:59+00:00
Accession:  0001213900-22-009481
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Helix enters $15M convertible loan with MoonLake; rollover option into PIPE
---------------------------------------------------------------------------

- Cormorant Private Healthcare Fund IV lends MoonLake $15M interest-free, unsecured, for general corporate purposes pending business combination.
- Loan matures 2 days after deal closing or June 30, 2022; may roll over into Cormorant's $27.5M PIPE commitment.
- If deal terminates, loan converts into MoonLake shares; subordinated to all creditors but senior to existing subordinated loans.
- Proceeds cannot be used to repay existing $15M loan from Biotechnology Value Funds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390022009481/0001213900-22-009481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390022009481/ea156204-8k_helixacq.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-009481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer